Quick Answer
Allogene Therapeutics, Inc. reported Research And Development Expense of $150.15 million for the year ending 2025.
- Allogene Therapeutics, Inc. showed a decrease of -21.9% in Research And Development Expense from 2024 to 2025.
- This data is from Allogene Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $122.49 million | Q3 2018: $10.87 million | Q1 2019: $23.40 million | Q2 2019: $31.77 million | Q3 2019: $40.00 million | Q1 2020: $42.04 million | Q2 2020: $47.30 million | Q3 2020: $51.42 million | Q1 2021: $55.18 million | Q2 2021: $52.29 million | Q3 2021: $58.72 million | Q1 2022: $60.16 million | Q2 2022: $57.17 million | Q3 2022: $63.64 million | Q1 2023: $80.24 million | Q2 2023: $62.04 million | Q3 2023: $45.98 million | Q1 2024: $52.26 million | Q2 2024: $50.36 million | Q3 2024: $44.71 million | Q1 2025: $50.20 million | Q2 2025: $40.16 million | Q3 2025: $31.16 million.
- Historical annual values: Fiscal year 2025: $150.15 million | Fiscal year 2024: $192.30 million | Fiscal year 2023: $242.91 million | Fiscal year 2022: $256.39 million | Fiscal year 2021: $220.18 million | Fiscal year 2020: $192.99 million | Fiscal year 2019: $144.54 million | Fiscal year 2018: $151.86 million | Fiscal year 2017: $0.00.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: